The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The company is excluding data from the affected sites to maintain the study's integrity
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
